Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
5.77 -0.07 (-1.20%) 03/07/25 [NYSE]
5.61 x 100 5.87 x 100
Realtime by (Cboe BZX)
5.61 x 100 5.87 x 100
Realtime 5.67 -0.10 (-1.73%) 19:14 ET
Quote Overview for Fri, Mar 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.61
Day High
6.06
Open 5.81
Previous Close 5.84 5.84
Volume 936,400 936,400
Avg Vol 1,426,205 1,426,205
Stochastic %K 15.52% 15.52%
Weighted Alpha -15.27 -15.27
5-Day Change -1.71 (-22.86%) -1.71 (-22.86%)
52-Week Range 1.82 - 15.10 1.82 - 15.10
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 317,328
  • Shares Outstanding, K 54,337
  • Annual Sales, $ 1,049 M
  • Annual Income, $ -760,500 K
  • EBIT $ -78 M
  • EBITDA $ 287 M
  • 60-Month Beta 1.80
  • Price/Sales 0.30
  • Price/Cash Flow 3.02
  • Price/Book 0.65

Options Overview Details

View History
  • Implied Volatility 233.22% ( -115.70%)
  • Historical Volatility 69.18%
  • IV Percentile 99%
  • IV Rank 62.40%
  • IV High 348.92% on 03/06/25
  • IV Low 41.21% on 09/11/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 205
  • Volume Avg (30-Day) 672
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 16,204
  • Open Int (30-Day) 15,362

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.70
  • Number of Estimates 2
  • High Estimate 1.14
  • Low Estimate 0.27
  • Prior Year 0.59
  • Growth Rate Est. (year over year) +18.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.04 +14.48%
on 03/04/25
Period Open: 10.00
10.49 -45.00%
on 02/10/25
-4.23 (-42.30%)
since 02/07/25
3-Month
5.04 +14.48%
on 03/04/25
Period Open: 9.01
11.98 -51.84%
on 01/24/25
-3.24 (-35.96%)
since 12/06/24
52-Week
1.82 +217.02%
on 04/18/24
Period Open: 2.77
15.10 -61.79%
on 07/30/24
+3.00 (+108.30%)
since 03/07/24

Most Recent Stories

More News
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

Jazz Pharmaceuticals JAZZ announced that it has entered into a definitive agreement to acquire all the outstanding shares of clinical-stage biotech Chimerix CMRX for $8.55 per share in cash, aggregating...

JAZZ : 138.81 (+1.73%)
EBS : 5.77 (-1.20%)
CMRX : 8.43 (unch)
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

EBS : 5.77 (-1.20%)
AVUV : 88.68 (+0.62%)
VTI : 283.34 (+0.47%)
XBI : 87.30 (+0.28%)
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript

EBS earnings call for the period ending December 31, 2024.

EBS : 5.77 (-1.20%)
Emergent Biosolutions: Q4 Earnings Snapshot

Emergent Biosolutions: Q4 Earnings Snapshot

EBS : 5.77 (-1.20%)
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

EBS : 5.77 (-1.20%)
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

EBS : 5.77 (-1.20%)
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

EBS : 5.77 (-1.20%)
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

EBS : 5.77 (-1.20%)
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

EBS : 5.77 (-1.20%)
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebangaâ„¢ (ansuvimab-zykl) Treatment for Ebola

EBS : 5.77 (-1.20%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 6.47
2nd Resistance Point 6.26
1st Resistance Point 6.02
Last Price 5.77
1st Support Level 5.57
2nd Support Level 5.36
3rd Support Level 5.12

See More

52-Week High 15.10
Fibonacci 61.8% 10.03
Fibonacci 50% 8.46
Fibonacci 38.2% 6.89
Last Price 5.77
52-Week Low 1.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights